

Other focused conferences during WorldPharma2010

- 1: Clinical pharmacology in emerging and developing countries
- 2: Transmembrane transport: perspectives for disease and drug discovery
- 3: Ion channels in analgesia and anaesthesia
- 5: Translational science in the metabolic syndrome: basic and clinical pharmacology
- 6: The heart gone wrong; stabilization of cardiac function
- 7: Simulation and data modelling in drug development. Better drugs faster?
- 8: Developments in the treatment of sexual dysfunction and diseases of the lower urinary tract
- 9: Inflammation and immunopharmacology: new tools for old diseases
- 10: Drugs for half the world: paediatric clinical pharmacology
- 11: G protein-coupled 7TM receptors:
from molecular to physiological function
- 12: Ion channelopathies:
new windows on complex disease and therapy
- 13: Maximising benefits and minimizing harms from drugs
- 14: Addiction and doping:
neurobiological and clinical basis of emerging treatments
- 15: Endothelium in health and disease
- 16: Natural products: past and future?
- 17: New approaches and targets in psychiatry
- 18: Nuclear receptor targets for treatment of diseases

Danish Society for 
Pharmacology



BCPT
Basic & Clinical Pharmacology & Toxicology



Printed in Denmark

Please find further details on www.WorldPharma2010.org



WorldPharma2010

16th World Congress on Basic and Clinical Pharmacology.
July 17-23, 2010, Copenhagen, Denmark

WorldPharma2010 will include a
2-day focused conference on

**Pharmacoepidemiology,
current controversies and
opportunities**

19-20 July 2010

Abstract deadline 15 January 2010
Early bird registration deadline 15 March 2010

Invitation

July 17-23 2010 is the time for a major event for pharmacology, the science of how drugs affect the living organism. Basic and clinical pharmacology, kept separate for too long, have come together again to encompass the whole process of drug development from molecular biology to clinical practice. This remarriage is to be celebrated in Copenhagen; the world's basic and clinical pharmacologists and all those dealing with the development and use of drugs will meet to discuss how we can work together to meet the need for safe and effective medicines at affordable prices.

WorldPharma2010 is organised by the Danish Society for Pharmacology jointly with the British Pharmacological Society under the auspices of the International Union of Basic and Clinical Pharmacology, IUPHAR.

In the scientific programme, there will be plenary lectures, poster sessions, sponsored symposia, workshops, satellite meetings and focused conferences. Each of the 18 focused conferences contains 4 or 5 half-day sessions all belonging to the same theme. Overleaf is the detailed programme for the focused conference entitled:

"Pharmacoepidemiology, current controversies and opportunities"

The titles of the other focused conferences are listed on the back of the folder.

In each session there will be free communications as well. We promise you a scientifically excellent programme as well as the opportunity to savour the atmosphere of Copenhagen.



Kim Brøsen
President



Michael Mulvany
Secretary General

Congress secretariat

ICS A/S Copenhagen

Strandvejen 169-171 - P.O. Box 41 - DK-2900 Hellerup, Copenhagen - Denmark
Email: WorldPharma2010@ics.dk - Phone: +45 7023 7823 - Fax: +45 7023 7888

www.worldpharma2010.org



Pharmacoepidemiology, current controversies and opportunities

Focused conference leaders: Jesper Hallas & Bert Leufkens

Session 1 Methodological issues in pharmacoepidemiology

Chairpersons:
J. Hallas & T. Stürmer

- Immortal and immeasurable time in pharmacoepidemiology
S. Suissa, Canada
- Healthy initiators and sick stoppers
R. J. Glynn, USA
- Natural experiments in pharmacoepidemiology
O. H. Klungel, Netherlands
- Treatment decisions and propensity scores
T. Stürmer, USA

Session 2 Advanced methods for signal generating in claims databases

Chairperson:
A. Bate

- Methods for screening longitudinal electronic healthcare records
A. Bate, Sweden
- The US based Sentinel Initiative – status, potential and future possibilities
R. Platt, USA - TBC
- The Observational Medical Outcomes Partnership (OMOP) initiative
- What it is, its importance and results so far
P. Stang, USA
- An international perspective on screening for adverse effects of drugs and vaccines – how far can and should active surveillance go?
S. J. W. Evans, UK

Session 3 Regulatory challenges in managing risk of medicinal products

Chairperson:
B. Leufkens

- What are the issues driving the regulatory agenda on drug safety and risk management?
J. M. Raine, UK - TBC
- Are the available research methods sufficiently valid to address current benefit-risk issues on medicinal products?
S. J. W. Evans, UK
- New approaches to fill the methods gap in pharmacovigilance
M. de Bruin, Netherlands
- Is science enough to enforce appropriate regulatory decision making on drug safety?
D. J. Graham, USA - TBC

Session 4 In utero exposure to drugs

Chairpersons:
C. de Vries & L. T. W. de Jong-van den Berg

- Determining drug effects
- clinical considerations when establishing birth outcomes
L. T. W. de Jong-van den Berg, Netherlands
- The impact of thalidomide and its revival as a vital medicine. Lessons learned from history
T. D. Stephens, USA
- Pharmacological considerations of drug teratogenicity – why animal studies are not sufficient
TBA
- Unique methodological features in the pharmacoepidemiology of birth defects
C. de Vries, UK